Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
In phase 2 study, idecabtagene vicleucel, a B-cell maturation antigen–directed CAR T-cell therapy, induced responses in majority of heavily pretreated patients, with 94 of 128 patients (73%) having a response to treatment, and almost all patients had grade 3 or 4 toxic effects.
Source:
New England Journal of Medicine